摘要
目的研究α甲酰基辅酶A消旋酶(P504S)在结直肠癌(CRC)和正常结直肠黏膜中的表达及其临床意义。方法采用免疫组织化学方法检测江门市中心医院2017年1~12月共77例首发CRC手术根治切除标本和30例癌旁正常黏膜中P504S的表达水平。结果P504S在CRC中的阳性表达率为76.6%(59/77),显著高于正常大肠黏膜组织的3.3%(1/30),差异有统计学意义(P<0.01)。P504S在高-中分化腺癌中的阳性表达率为93.1%(54/58),显著高于低-未分化腺癌中的26.3%(5/19),差异有统计学意义(P<0.01);P504S在浸润深度为T1+T2中的阳性表达率为73.1%(19/26),在浸润深度为T3+T4中的阳性表达率为78.4(40/51),两者比较,差异无统计学意义(P>0.05);有淋巴结转移CRC中P504S的阳性表达率为83.3%(40/48),无淋巴结转移CRC中的阳性表达率为65.5%(19/29),两者比较,差异无统计学意义(P>0.05)。结论P504S参与介导CRC的发生发展进程,对CRC进展、预后及指导肿瘤的术后辅助治疗有重要的临床意义。
Objective To study the expression and clinical significance ofα-methylacyl-CoA racemase(P504 S)in colorectal cancer(CRC)and normal colorectal mucosa.Methods Immunohistochemical method was used to detect the expression level of P504 S in 77 specimens with primary CRC resection and 30 cases of adjacent normal mucosa from January to December 2017 in Jiangmen Central Hospital.Results The positive expression rate of P504 S in CRC was 76.6%(59/77),which was significantly higher than 3.3%(1/30)in normal colorectal mucosa,and the difference was statistically significant(P<0.01).The positive expression rate of P504 S in high-medium differentiated adenocarcinoma was 93.1%(54/58),which was significantly higher than that in low-undifferentiated adenocarcinoma accounting for 26.3%(5/19),and the difference was statistically significant(P<0.01).The positive expression rate of P504 S in infiltration depth of T1+T2 was 73.1%(19/26),and the positive expression rate in infiltration depth of T3+T4 was 78.4(40/51),and the difference was not statistically significant(P>0.05).The positive expression rate of P504 S in CRC with lymph node metastasis was83.3%(40/48),the positive expression rate in CRC without lymph node metastasis was 65.5%(19/29),and the difference was not statistically significant(P>0.05).Conclusion P504 S is involved in mediating the development of CRC,and it has important clinical significance for the progression,prognosis and postoperative adjuvant therapy of CRC.
作者
陈萍
万霞
刘琼茹
CHEN Ping;WAN Xia;LIU Qiong-ru(Department of Pathology,Jiangmen Central Hospital,Guangdong Province,Jiangmen 529000,China)
出处
《中国当代医药》
2019年第21期12-14,F0003,共4页
China Modern Medicine
基金
广东省江门市医疗卫生领域科技计划项目(2017A4006)
